ECM
SPRY icon

Endurant Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Endurant Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-84,295
Closed -$561K – 83
2021
Q4 		$561K Buy
+84,295
New +$685K 0.14% 66
2021
Q3 		– Sell
-139,124
Closed -$4.3M – 61
2021
Q2 		$4.3M Buy
+139,124
New +$4.46M 1.18% 33

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Endurant Capital Management's SPRY Position: Q1 2022 in Review

Endurant Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2022, closing a stake of 84,295 shares — an estimated $561K sold.

Endurant Capital Management first reported a position in SPRY in Q2 2021 and held it in 2 quarters. The position peaked at $4.3M in Q2 2021. 70 funds tracked by Wall St. Rank hold SPRY as of Q1 2022.

  • Endurant Capital Management reported no remaining ARS Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Endurant Capital Management sold 84,295 ARS Pharmaceuticals shares in Q1 2022, an estimated $561K.
  • Endurant Capital Management first reported a position in ARS Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Endurant Capital Management's ARS Pharmaceuticals position peaked at $4.3M in Q2 2021.
  • 70 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2022.

Based on Endurant Capital Management's 13F filing for Q1 2022, filed 16 May 2022.